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Letter to the Editor
Bordetella pertussis Polymorphism and Pertussis Vaccines
The topic of the article by Bottero et al. (1) is an important 
one, a bacterial vaccine for a preventable disease, pertussis. 
Many articles have been published on the subject in the last 10 
years (for a review, see reference 6). In their study, Bottero et 
al. neither followed the recommendations of consensus meet­
ings nor used published nomenclature. Furthermore, they 
compared vaccines that cannot be compared.
In the abstract and throughout the manuscript, the authors 
claim that the vaccines are not protecting against new circu­
lating isolates. How can they say that during the clinical efficacy 
trials, the isolates circulating in the countries where these trials 
were performed differed from the vaccine strains (at least in 
Europe) and then say that the vaccines were still found to be 
efficacious? We all agree that the actual isolates “escape” the 
herd immunity, but with the high level of vaccination coverage 
and the efficacy of whole-cell vaccines, these isolates can be 
controlled in many countries.
According to the description in Materials and Methods (1), 
Bottero et al. also did not use standardized techniques. For the 
PCR diagnosis, they did not use the agreed-upon reference 
technique published in 2005 (7). For the pulsed-field gel elec­
trophoresis (PFGE) analysis, they cite the reference paper of 
Mooi et al. (5) but did not follow all of its conditions, which are 
now used by all other teams in Europe and the United States 
(3). Further, they use numbers to differentiate the isolates 
which are similar to, but not the same as, those used by Mooi 
et al., and this is very confusing for all readers. Also, they write 
that the Tohama strain is a vaccine strain, which is not the case 
in their country. For the animal assay, they cite the reference 
paper authored by myself and my colleagues (4) but do not 
follow the same protocol. We did not use intraperitoneal ad­
ministration and did not conclude that 1/10 of the human dose 
of the vaccine is the right dose for an animal. Furthermore, as 
this test is now one of the World Health Organization’s assays 
for licensing vaccines (8), it is important to follow the proce­
dures for this assay exactly. Also, how can anyone dare to 
compare an unidentified combined diphtheria-tetanus-whole- 
cell pertussis vaccine (no source, manufacturer, or other infor­
mation provided) with a noncombined, apparently homemade 
vaccine with no description of the technique used to detoxify 
the bacteria?
In Results and Discussion of their paper (1), the authors 
omit any comparison or discussion of the data from Argentina 
that my colleagues and I obtained and published recently about 
the same isolates that they used (2). Nor do they refer to the 
many studies performed in Europe and elsewhere on the same 
topic. The data presented concerning the animal model in­
clude the data at day 5 but no data for day 8. They neither 
discuss nor cite data previously published on whole-cell per­
tussis vaccine-induced immunity against infection due to dif­
ferent isolates, but they do present a superficial analysis of one 
clinical isolate without any confirmation of the data for at least 
two or three other isolates of the same PFGE groups.
For these many and various reasons, I advise caution in 
interpreting the paper of Bottero et al., which sits uncomfort­
ably with much of the already available literature on pertussis 
strains.
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Author’s Reply
First, I want to clarify for Dr. Guiso that in no part of our 
paper (1) did we state that “the vaccines are not protecting 
against new circulating isolates.” Therefore, I recommend a 
more careful reading of our work in order to determine the 
true subject under discussion. My colleagues and I will not 
argue about what is not stated in the article. On the other 
hand, it is important to point out that all protection results 
presented in our paper were obtained using mice, and thus, 
care in making extrapolations to humans must be taken.
It remains difficult to prove that changes observed in B. 
pertussis populations affect vaccine efficacy in humans. To 
prove this requires at least a clinical trial with two vaccines, one 
derived from old strains and one from current isolates. To our 
knowledge, this kind of study has not yet been done.
As for Dr. Guiso’s claim that we did not use standardized 
techniques, I want to point out that there are no universal 
standardized PCR protocols for Bordetella pertussis. Various 
single-target PCR assays are currently utilized, but none is 
universally considered to be the “gold standard.” The paper on 
the agreed-upon reference technique for PCR diagnosis men­
tioned by Dr. Guiso (6) was written by M. Riffelmann, C. H.
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Wirsing von König, V. Caro, and N. Guiso for the Pertussis 
PCR Consensus Group. The protocol described in the article is 
very sensitive but lacks specificity in terms of Bordetella species. 
In fact, this PCR assay also detects Bordetella holmesii, Borde­
tella petrii, and Bordetella bronchiseptica isolates. Moreover, 
after publication of the article, additional different assays were 
proposed (3, 5). The important point is to avoid the use of the 
PCR as a unique method, separate from other diagnostic tech­
niques and the clinical characteristics of the case. We have 
several years of experience in molecular diagnostic methodol­
ogy, and good correlation between the PCR method we used 
and other diagnostic methodologies was observed. For the 
PFGE analysis, we followed the conditions reported by Mooi 
et al. (4), but as usual, we had to introduce minor changes to 
set up the technique in our lab. We do not think that the 
numbers used to differentiate the isolates were “very confusing 
for all readers.” Comparison of the data from Argentina with 
those obtained by Dr. Guiso’s group has already been done, so 
we considered it redundant to repeat it. For the animal assay, 
we followed the intranasal challenge model reported by Guiso 
et al. (2). As for the conditions reported in Materials and 
Methods, we consistently observed differences in the protec­
tion levels, which had to be communicated. Throughout her 
letter, Dr. Guiso criticizes not the validity of our experiments 
but whether we used standardized techniques. The important 
point here is that by applying all rigorous controls and repro­
ducibility tests to our methodologies, we found coherent re­
sults on divergence from immunogen sequencing, PFGE, pro­
teomics, and animal assays. Data for days 5 and 8 were 
included when mice were immunized with the commercial vac­
cine and challenged with the different strains. We do not un­
derstand why Dr. Guiso claims the contrary. In the case of the 
mice immunized with wPBplOö, we presented the data ob­
tained on days 0 and 5, since differences in protection at such 
times were already evident.
The Tohama strain was used in these experiments because it 
was isolated during the same period as the other vaccine 
strains, and because of that, it is considered an old strain, 
which is the important point: it is used for acellular pertussis 
vaccine production, and its genome is completely sequenced. It 
is important to emphasize that we are convinced that the cur­
rent vaccines are effective but not the best. However, it will be 
important to keep analyzing the relevance that divergences 
between circulating bacteria and strains used in vaccine pro­
duction have on protection. Our results show that circulating 
bacteria differ at the genome and proteome levels from strains 
used in vaccine production and, moreover, that divergence 
between strains affects vaccine efficacy in an intranasal chal­
lenge mouse model. These results do not mean that pertussis 
vaccines are not protecting humans.
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